Compare Gilead Sciences, Inc. (GILD) vs Goodyear Tire & Rubber Co (GT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Goodyear Tire & Rubber Co — how do they compare? Gilead Sciences, Inc. trades at $151.17 (market cap $182.40B), while Goodyear Tire & Rubber Co trades at $4.68 (market cap $1.37B). The key difference: Gilead Sciences, Inc. is far larger — about 133.1× Goodyear Tire & Rubber Co's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while Goodyear Tire & Rubber Co pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Goodyear Tire & Rubber Co for 57 Days on average.
| GILD | GT | |
|---|---|---|
Market Cap | $182.40B | $1.37B |
Volume | 4,469,821 | 9,470,773 |
Sector | Health | Consumer Cyclical |
52-Week High | $155.80 | $10.54 |
52-Week Low | $117.18 | $4.66 |
Typical Hold Time | 111 Days | 57 Days |
Enterprise Value | $205.46B | $8.72B |
Dividend Yield | 2.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $147.10, up 0.17% on the day, with a bullish technical signal and strong analyst consensus. Recent earnings have mostly beaten expectations, though Q2 2026 saw a significant loss. The company maintains robust operating cash flow and has expanded access to its HIV prevention drug lenacapavir in Latin America, signaling growth potential in its core franchises.
The outlook is positive given analyst buy ratings and a $151.57 price target, but risks include negative net income margin and ROE in 2026, high debt levels, and reliance on pipeline success. The stock offers value if HIV and oncology advances materialize, yet investors face volatility from earnings inconsistencies and competitive pressures.
Goodyear Tire & Rubber (GT) trades at $4.75, down 1.28% with bearish technical signals. The company faces significant challenges with a net loss of $1.72 billion in 2025 and negative profit margins, though valuation ratios appear attractive with P/E of 4.69 and P/B of 0.48. Recent earnings show mixed results with Q2 2026 beating expectations but still posting losses. Cash flow improved to $46 million in 2025, while debt remains elevated at $7.78 billion total.
The outlook remains challenging with ongoing restructuring efforts and volume pressures. Analyst consensus is mixed with 34.6% buy ratings but a $8.00 price target suggesting 68% upside. Key risks include execution of turnaround plan, competitive pressures, and high debt load. The stock's current valuation discounts much of the negativity, creating potential for recovery if management delivers on margin improvement targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Goodyear Tire & Rubber Co
Goodyear Tire & Rubber Co manufactures and sells a variety of rubber tires under the Goodyear brand name. The firm's tires are used for automobiles, trucks, buses, aircraft, motorcycles, mining equipment, farm equipment, and industrial equipment.
Read more on GT →
